PRESS-RELEASE ·Filed Mar 18, 2026
Press release · Earnings
Actionable Insight • Neutral
Traders should monitor the March 24 earnings release and call for revenue, EPS, and guidance updates, particularly on PEDMARK/PEDMARQSI sales trends and U.S. commercial execution.
Final — all horizons settled through T+60d
FENC ▲ +18.47% at T+60d
NEUTRAL call +18.47% · α vs SPY +6.95% · entry $7.47 → $8.85
T+1d
+2.41%
call +2.41% · α +2.68%
$7.65
settled 7mo ago
T+5d
-17.40%
call -17.40% · α -16.69%
$6.17
settled 7mo ago
T+20d
-15.66%
call -15.66% · α -21.71%
$6.30
settled 6mo ago
T+60d
+18.47%
call +18.47% · α +6.95%
$8.85
settled 5mo ago
Price Chart
Loading chart...
Executive Summary
Fennec Pharmaceuticals announced it will release its full year and fourth quarter 2025 financial results on March 24, 2026, followed by a management conference call. The press release contains no actual financial data, only logistical details for the upcoming earnings announcement.
Key Facts
- Fennec Pharmaceuticals will release full year and Q4 2025 financial results on March 24, 2026, before market open.
- Management will host a conference call and webcast on March 24, 2026, at 8:30 a.m. ET to discuss results.
- No financial figures (revenue, EPS, etc.) were disclosed in this announcement.
- PEDMARK is approved in the U.S. and PEDMARQSI in Europe, U.K., with commercial availability in U.K. and Germany.
- Norgine Pharmaceuticals holds exclusive rights to commercialize PEDMARQSI in Europe, U.K., Australia, and New Zealand.
Financial Impact
None disclosed — actual financial results not included in this release
Risk Factors
- Lack of disclosed financials limits near-term trading catalysts ahead of the March 24 release.
- Revenue concentration in a single product (PEDMARK) creates execution and adoption risk.
Market Snapshot
Exchange
Nasdaq
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258049 |
18 reports for FENC
100% Hit rate @ T+60 Went positive at some point 4 of 5 best @ T+60▲ +50.50%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.15 (−1.17%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.15 (−20.58%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.15 (+10.45%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.15 (+2.63%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.15 (+4.00%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.15 (+9.85%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.15 (+47.10%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.15 (+62.14%) |
Showing 10 of 18
US Market Status
Market Closed — Opens in 1h 25m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers